The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.

Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study, rats bearing a hind limb soft tissue sarcoma underwent ILP using different combinations of melphalan, TNF and cilengitide in the perfusate. Further groups had intra-peritoneal (i.p.) injections of cilengitide or saline 2 hr before and 3 hr after ILP. A 77% response rate (RR) was seen in animals treated i.p. with cilengitide and perfused with melphalan plus cilengitide. The RR was 85% in animals treated i.p. with cilengitide and ILP using melphalan plus both TNF and cilengitide. Both RRs were significantly greater than those seen with melphalan or cilengitide alone. Histopathology showed that high RRs were accompanied by disruption of tumor vascular endothelium and tumor necrosis. Compared with ILP using melphalan alone, the addition of cilengitide resulted in a three to sevenfold increase in melphalan concentration in tumor but not in muscle in the perfused limb. Supportive in vitro studies indicate that cilengitide both inhibits tumor cell attachment and increases endothelial permeability. Since cilengitide has low toxicity, these data suggest the agent is a good alternative to TNF in the ILP setting.

AMCHP Issue Brief: Environmental Scan: State Title V Program Response to Autism Spectrum Disorder and Other Developmental Disabilities, December 2009

The increasing incidence of children identified and diagnosed with Autism Spectrum Disorders (ASD) and other developmental disabilities (DD) poses a major challenge to Title V and other programs as they try to meet the diverse and sometimes complex needs of these children. However, those state that have initiated coordinated efforts to meet the needs of these children cross systems have had the opportunity to form and/or strengthen relationships with new partners. In addition, these coordinated efforts will allow states to develop new policies, programs and financing mechanisms addressing the health of children with ASD, which may also strengthen the system of care for all Children and Youth with Special Health Care Needs.

Maternal and Child Health Services Title V Block Grant State Narrative for Iowa Application for 2013 Annual Report for 2011

Key factors that provide context for the state's Maternal and Child Health (MCH) annual report and state plan are highlighted in this overview. This section briefly outlines Iowa's demographics, population changes, economic indicators and significant public initiatives. Major strategic planning efforts affecting development of program activities are also identified.

A.A.V.V.: Montbarbat (1978-1986), Lloret de Mar, 1996

Debe reconocerse que en estos años próximos al fin del milenio la publicación de estudios sobre el mundo ibérico goza de excelente salud, cuando menos en volumen. Artículos, ponencias y comunicaciones amenazan con abrumar al lector más impenitente. Por ello resulta aleccionador acudir al meritorio trabajo de Fernando Quesada: "La cultura ibérica: una aproximación bibliográfica (1992-1993)", RE/b, 1, 1994, 335-377, que reúne la producción en revistas y series no excesivamente locales -imposibles de controlar, por otro lado-, y comprobar un balance de unos doscientos títulos anuales. Ahora bien, si consideramos el número de monografías, nos situaremos en un plano selectivo, que rondará la docena al año. Diversos factores -y entre ellos la desidia de diferentes niveles administrativos y académicos- parecen confabularse para que no se disponga de un conjunto de memorias impresas proporcional al volumen de excavaciones realizadas en las dos últimas décadas.